



































































 Polysaccharide peptide induces a tumor necrosis factor-α-dependent drop of body 
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Polysaccharide peptide (PSP) extracted from the Coriolus versicolor mushroom is frequently 
suggested as an adjunct to the chemo- or radiotherapy in cancer patients. It improves quality 
of the patients‟ life by decreasing pain, fatigue, loss of appetite, nausea, and vomiting. 
However, the effect of PSP on body temperature has not thus far been studied, although it is 
well known that treatment with other polysaccharide adjuvants, such as lipopolysaccharides, 
may induce fever. The aim of the present study, therefore, was to investigate the influence of 
PSP on temperature regulation in rats. We report that intraperitoneal injection of PSP 
provoked a dose-dependent decrease of temperature in male Wistar rats equipped with 
biotelemetry devices to monitor deep body temperature (Tb). The response was rapid (i.e., 
with latency of 15-20 minutes), transient (lasting up to 5 hours post-injection), and 
accompanied by a significant elevation of the blood tumor necrosis factor- α (TNF-α) level. 
Pretreatment of the rats with anti-TNF-α antibody prevented the PSP-induced drop in Tb. 
Based on these data, we conclude that rats may develop an anapyrexia-like response to the 
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Polysaccharide peptide of the Coriolus versicolor mushroom (Cui and Chisti, 2003) has been 
recommended as an adjuvant in the treatment of cancer (Zaidman et al., 2005) and several 
other disorders, such as chronic hepatitis and infections of the upper respiratory, urinary, and 
digestive tracts (Eliza et al., 2012). The doses usually used range from 1 to 3.6 grams per day 
and the duration of therapy is from 1 to 36 months, depending on the patient's condition (Kid, 
2000). Experimental and clinical studies demonstrate that PSP extracts show non-toxic effects 
(Cheng and Leung, 2008), inhibit the growth of cancer cells in in vitro and in vivo settings 
(Tsang et al., 2003; Lau et al., 2004), and decrease cancer treatment-related symptoms such as 
fatigue, loss of appetite, nausea, vomiting, and pain (Chan and Yeung, 2006). It is suggested 
that the compound exerts its activity primarily via immunomodulation (Dong et al., 1996), 
therefore has been classified as a „biological response modifier‟ (Ng, 1998). Indeed, data 
demonstrate that PSP induces synthesis of pro-inflammatory cytokines, eicosanoids, 
histamine, reactive oxygen and nitrogen intermediates (Chan and Yeung, 2006; Schepetkin 
and Quinn, 2006), activates complement-3, and stimulates the NK activities and T-cell 
proliferation (Sekhon et al., 2013) among others. 
Immunomodulatory activities of the PSP, especially those data that show in vitro synthesis of 
interleukin-1β (IL-1β) and TNF-α by macrophages co-cultured with PSP (Schepetkin and 
Quinn, 2006) implicate that the use of the compound may exert a profound influence on the 
regulation of body temperature in men and in laboratory animals. These cytokines are 
particularly involved in the mechanism of fever induced by a large variety of the pathogen-
associated molecular patterns also called „exogenous pyrogens‟, including another 
polysaccharide „biological response modifier‟, i.e., lipopolysaccharides (LPS) extracted from 
the Gram-negative bacteria (Kluger, 1991; Kozak et al., 2000; Kozak et al., 2006a). However, 
to the best of our knowledge, the effect of PSP on body temperature regulation has not been 
studied. Based on experimental data reported from other laboratories using PSP we have put 
forward a hypothesis that polysaccharide peptide, similar to the action of LPS on body 
temperature, induces fever and the compound can be classified to the family of exogenous 
pyrogens. We report that instead of fever, PSP provokes a significant decrease of body 
temperature (Tb) in the rat. Since the in vitro studies showed that PSP stimulates the synthesis 
of TNF-α by macrophages (Schepetkin and Quinn, 2006), and in vivo research demonstrated 
that this cytokine can exert an anapyretic effect in rats (Evans et al., 1994; Klir et al., 1995) 




































































decreasing of body temperature of the rats treated with PSP.  We demonstrate that PSP-
provoked drop of Tb was prevented by treatment of rats with anti-TNF-α antibody. 
 
2. Materials and Methods 
2.1. Experimental animals and body temperature measurement 
Male Wistar rats weighing from 200 g to 250 g were obtained from the Mossakowski Medical 
Research Centre Polish Academy of Sciences (Warsaw, Poland). Animals were housed in 
individual plastic cages and maintained in a temperature/humidity/light-controlled chamber 
set at 23 ± 1°C, 12:12 h light:dark cycle, with light on at 07:00 a.m. Rodent laboratory food 
and drinking water were provided ad libitum. A week after the shipment, the rats were 
implanted under sterile conditions with battery-operated miniature biotelemeters (PhysioTel
®
 
model TA10TA-F40, Data Sciences International, USA) to monitor deep body temperature 
(Tb) with accuracy ± 0.1
o
C as described previously (Wrotek et al., 2011).  Described 
experiments were started 10 days after surgery. All procedures were approved by the Local 
Bioethical Committee for Animal Care in Bydgoszcz (Poland; permission no. 17/2013). 
 
2.2. Treatment of the animals 
Polysaccharide peptide (PSP; extract from the Cov 1 strain of Coriolus versicolor; 
MycoMedica, Czech Republic) was dissolved in sterile 0.9% sodium chloride (saline) and 
injected intraperitoneally (i.p.) at a dose of 50, 100 and 200 mg kg
-1
.  Control group of rats 
was treated i.p. with an equivalent volume of a pyrogen-free saline.  
TNF-α antibody (rabbit polyclonal IgG anti rat TNF-α; Thermo Scientific; cat. no. PRTNFAI) 
was injected i.p. at a dose of 50 µg/rat in a volume of 500 µl of phosphate buffered saline 
(PBS, pH 7.4) 1 h prior to the injection of PSP. Rabbit IgG (Rockland Immunochemicals; cat. 
no. 011-001-297) was used as control injection. Rats were restrained and not anesthetized 
during i.p. injections. 
 
2.3. TNF-α assay 
Blood samples were collected via cardiac puncture onto the solution of ethylenediamine 
tetraacetic acid disodium salt (Na2EDTA, Sigma-Aldrich; cat. no. E 5134) two hours post-
injection of PSP and/or pyrogen-free saline from rats anesthetized with a mixture of 
ketamine/xylazine (87 mg kg
-1
 and 13 mg kg
-1
, respectively, intramuscular injection),  After 




































































The levels of TNF-α were determined by a standard sandwich ELISA kit from R&D Systems 
(cat. no. RTA00; sensitivity of assay less than 5 pg ml
-1
) according to the manufacturer‟s 
instructions. Colorimetric changes in the assay were detected using Synergy HT Multi-Mode 
Microplate Reader (BioTek Instruments, USA). 
 
2.4. Statistical analysis 
All values are reported as means ± standard error mean (S.E.M.) and were analyzed by 
analysis of variance (ANOVA) followed by the Student‟s t-test with the level of significance 
set at P<0.05. ANOVA was used to compare the mean values in the all tested groups, whereas 
the Student‟s t-test was used to calculate the difference only between the two selected groups. 
For the conclusions of our study we used the Student‟s t-test. For the Tb measures, the data 
were recorded and computed at 5-min intervals using Data Acquisition Programme (Data 
Sciences International, USA). For data presentation, these 5-min temperature recordings were 
pooled into 20-min averages. 
 
3. Results 
3.1. Injection of PSP provokes a decrease in body temperature and elevation of blood TNF-α 
of rats 
Effect of PSP on changes of Tb in male Wistar rats is illustrated in Fig. 1. Three doses of the 
PSP (50, 100 and 200 mg kg
-1
) were injected intraperitoneally into the separate groups of rats. 
In the case of all doses of PSP, the response was rapid with latency of 15-20 min and transient 
(lasting up to 5 hours post-injection). Moreover, the maximum drop in Tb of rats was 
maintained from 45 min to 2 h after PSP administration. However, the decrease in Tb was 
dose-dependent. PSP at a dose of 50 mg/kg induced a decrease in Tb to 36.3 ± 0.2
o
C 
(measured at 90 min post-injection), whereas the doses of 100 mg kg
-1
 and 200 mg kg
-1
 
provoked a similar greater drop in Tb to 35.8 ± 0.2
o
C and 35.6 ± 0.1
o
C, respectively at the 
same time (P<0.05). Dose of 100 mg kg
-1 
of PSP was selected for further experiments. 
Injection i.p. of sterile saline (solvent for PSP) did not induce any alterations in Tb of rats 
(data not shown).  
(Insert Figure 1 here) 
 Rats injected i.p. with saline (control vehicle) as well as non-treated animals did not 
show any significant elevation of TNF-α at 2 h post-injection (Fig. 2). Plasma concentration 
of the cytokine in these two groups of rats was below the lowest standard of ELISA kit 
(respectively 3.07 ± 0,2 pg ml
-1
 and 2.13 ± 0,2 pg ml
-1






































































). In contrast, however, the levels of TNF-α in plasma of the rats treated with PSP at a dose 
of 100 mg kg
-1
 2h post-injection were significantly higher (225 ± 4 pg ml
-1
). Blood for 
analyses was collected at the time of the greatest decrease in body temperature of rats. 
(Insert Figure 2 here) 
 
3.2. Administration of TNF-α antibody inhibited a decrease in body temperature of rats 
injected with PSP  
 To determinate whether or not the TNF-α is involved in a PSP-induced decrease of Tb, 
in separate experiments rats were treated i.p. with an anti-TNF-α immunoglobulin G (IgG) at 
a dose of 50 µg/rat 1 h prior to the injection of PSP at a dose 100 mg kg
-1
. As can be seen in 
Fig. 3, administration of TNF-α antibody inhibited the decrease of Tb provoked by the 
injection of PSP. The Tb of rats treated i.p. with TNF-α antibody and then injected with PSP 
was similar to that observed in the control rats injected i.p. with rabbit IgG 1 h prior to the 
administration of 0.9% saline (37.1 ± 0.1
o
C and 37.2 ± 0.1
o
C, respectively; P=0.38; counting 
from 0 min to 240 min post-injection). On the other hand, the Tb of rats injected i.p. with 
rabbit IgG at a dose of 50 µg kg
-1
 1 h prior to the injection of PSP (100 mg kg
-1
) was 
significantly lower in this period of time (36.1 ± 0.4
o
C; P<0.001). Moreover, the rats injected 
with IgG and then with PSP responded with a similar drop in Tb as the group of animals 
treated i.p. only with PSP. In both groups of animals, the response was similarly rapid (with 
latency of 15-25 min), transient (lasting up to 5 hours post-injection) and with the same 
maximum drop in Tb (35.6 ± 0.1
o
C and 35.8 ± 0.2
o
C, respectively; measured at 90 min post-
injection). 
(Insert Figure 3 here) 
 
4. Discussion 
 In the present report we demonstrate for the first time that polysaccharide peptide, a 
bioactive component derived from the mushroom Coriolus versicolor, which exhibits 
antitumor and immunomodulatory properties, provoked also a dose-dependent decrease in 
body temperature of rats (Fig. 1). Moreover, we have shown that the drop in Tb was 
accompanied by a significant elevation of the blood TNF-α level of rats 2h post-injection 
(Fig. 2), and was prevented by an i.p. injection of anti-TNF-α antibody 1h prior to the PSP 
administration (Fig. 3). 
 Nowadays, PSP is considered as an useful adjuvant especially combined with 




































































revealed that PSP is able to restore weakened immune response observed in patients with 
cancer or during chemotherapy (Chu et al., 2002). Moreover, PSP stimulates an element of 
the innate immune system, which markedly influences the host‟s ability to respond to various 
external stimuli, including pathogenic microorganisms. Phagocytic cells such as neutrophils 
and macrophages are a key component of the innate immune system. They represent the first 
line of the defense and are involved in all phases of the immune response (phagocytosis, 
antigen presentation, cytokine secretion) (Dempsey et al., 2003; Wynn et al., 2013). Data 
indicate that PSP is capable to restore and enhance the phagocytic function of macrophages 
and it stimulates these cells to the release of pro-inflammatory cytokines (IL-6, TNF-α, IL-1) 
and prostaglandin E2 (PGE2) (Chan and Yeung, 2006). It is well-known that all these 
activities are temperature-dependent. Based on these data one may conclude that 
understanding of the effect of PSP on body temperature is very important, especially when 
considering PSP as an useful adjuvant in clinical treatment of cancer patients or during the 
severe infections.  
 PSP is used as an anticancer and immunomodulatory agent. Although the mechanism 
of its antitumor action is still not completely clear, this polysaccharide is suggested to enhance 
cell-mediated immune response in vivo and in vitro and act as biological response modifiers. 
PSP is considered as multi-cytokine inducer that is able to induce gene expression of various 
immunomodulatory cytokines, such as IL-1β, TNF-α, IFN-γ (Ooi and Liu, 2000; Lee et al., 
2006). Moreover, PSP regulates gene expression and cytokine secretion related to Toll-like 
receptors (TLRs) signaling pathway. In human peripheral blood mononuclear cells, TRAM-
TRIF-TRAF6 subsignaling pathway of TLR seems to be one of the key associated signaling 
pathways in the immunomodulation of PSP (Li et al., 2010). Thus, polysaccharide peptide 
may constitute the pathogen-associated molecular patterns (PAMPs) recognized by TLRs. It 
is well-known that many PAMPs activate a common downstream pathway operating in the 
signal transduction via TLRs, that leads to the upregulation of the nuclear factor-κB (NF-κB) 
- one of the most important transcription factors which can induce cytokine genes expression, 
including TNF-α (Kozak et al., 2006a; Kaisho and Akira, 2001; Baeuerle and Henkel, 1994).  
 TNF-α is a circulating 17-kDa protein that interacts with two distinct transmembrane 
signaling receptors, termed the type I (p55) and the type II (p75), to induce its biological 
effects (Schall et al., 1990). Injection of exogenous TNF-α is capable of causing fever in 
healthy animals of several species (Netea et al., 2000). The pyrogenic properties of the 
cytokine are induced by binding TNF-α with the type II receptor (Leon et al., 1997; Kozak et 




































































or antipyretic effect when this cytokine is bound with type I receptor (Evans et al., 1994; Klir 
et al., 1995). Anapyrexia is defined as a regulated decrease in core temperature distinct from 
hypothermia in that thermoregulatory responses indicate a defense of the anapyretic level of 
core temperature (Glossary of Terms for Thermal Physiology, 2001). There are conditions 
under which anapyrexia appears to be adaptive rather than pathologic (Kozak, 1997). For 
instance, upon hypoxic circumstances (i.e., during anemia, ischemia, cardiac arrhythmias, 
hypotension) anapyrexia protects tissues from the lack of oxygen by decreasing its 
consumption and by slowing the rate of cellular damage that occurs from the formation of free 
radicals, chemical metabolites and tissue edema (Steiner and Branco, 2002; Kozak et al., 
2006b). It‟s assumed that the process may be mediated or initiated by a “cryogen”, defined as 
an endogenous or exogenous substance that lowers the set point of deep body temperature 
(Kluger, 1991). Our studies demonstrate that PSP may induce an anapyrexia-like effect, 
which may be mediated by TNF-α. However, in order to fully investigate this phenomenon it 
is necessary to measure the behavior and autonomic responses to determine the regulated 
nature of the hypothermia following treatment with PSP. Because of the fact that anti-tumor 
properties of PSP are postulated, we hypothesized that this phenomenon is associated with the 
rise in plasma TNF-α.  
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Figure 1. Changes of body temperature (
o
C) over time (min) of rats injected intraperitoneally 
(i.p.) at 0 time (arrowhead) with PSP at a dose 50 mg kg
-1
 (open triangles), 100 mg kg
-1
 (close 
diamonds) and 200 mg kg
-1
 (open circles) in comparison to non-treated animals (close 
circles). Values are means ± S.E.M. at 20-min averages (n indicates sample size in a 
respective group).  
Figure 2. Plasma levels of TNF-α (pg ml
-1
) at 2 h post-injection of PSP at a dose of 100 mg 
kg
-1
 and control injection of saline in comparison to non-treated animals (control). Values are 
expressed as means ±S.E.M; n depicts sample sizes for each group. Asterisk indicates 
significant difference compared to the control and saline i.p. (***P<0.001; *P<0.05, 
respectively). 
Figure 3. Changes of body temperature (
o
C) over time (min) of rats injected i.p. at -60 time 
(black arrowhead at 08:00 a.m.) with anti-rat TNF-α IgG (50 μg/rat) or IgG (50 μg/rat) and 
then treated i.p. at 0 time (white arrowhead at 09:00 a.m.) with PSP (100 mg kg
-1
) or with 
0.9% saline in comparison to rats injected i.p. with PSP (100 mg kg
-1
) at 0 time. Values are 
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 we examine the effect of polysaccharide peptide (PSP) on rat body temperature (Tb) 
 injection of PSP provokes a dose-dependent decrease of body temperature in rats 
 decrease of temperature is accompanied by an elevation of the blood TNF-α level 
 rats pretreatment with anti-TNF-α antibody prevents the PSP-induced drop in Tb 
 rats developed an anapyrexia-like response to the injection of PSP 
*Highlights (for review)
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
